---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-26-000041"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2026-05-12T20:10:14+00:00"
generated_at: "2026-05-12T21:22:01.267663+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zentalis Q1 2026 cash $211.8M; selects pivotal azenosertib dose; DENALI readout by year-end

## Summary
- Cash, cash equivalents and marketable securities $211.8M as of March 31, 2026; provides runway into late 2027.
- Selected 400mg QD 5:2 as pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC based on DENALI Part 2a interim.
- DENALI Part 2 topline readout expected by year-end 2026; potential accelerated approval pathway.
- ASPENOVA Phase 3 confirmatory trial in Cyclin E1-positive PROC initiated with first patient dosed.
- Q1 total operating expenses $37.9M, down from $45.6M (includes $7.8M non-recurring restructuring in prior year).

## SEC filing metadata
- accession: 0001725160-26-000041
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2026-05-12T20:10:14+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000041/0001725160-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000041/zntl-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-26-000041
- JSON: https://secwatch.observer/filing/0001725160-26-000041.json
- Plain text: https://secwatch.observer/filing/0001725160-26-000041.txt

## Key facts
- Earnings Releases
  Zentalis Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 12, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000041/0001725160-26-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.